AG22 Competitors

Some 45 years ago, we set out with the ambitious goal of providing affordable housing, working to make Brazilian dreams come true. Over the last few years, we have crafted and shaped our story, becoming a brand-leading platform that offers a variety of housing solutions for individuals and families from all walks of life – after all, each person is an individual – and every individual is as important as the next. Our company has joined together the efforts of some 30,000 staff members aiming to build dreams that transform the world – because we believe that purchasing a home is not the end of the line, but the beginning of life-changing transformation and the origin of many dreams for the future. Our company is present in more than 160 cities and 22 states, seeking to bring quality of life, comfort and innovation to the doorstep of thousands of families. And it is our great pleasure to announce that, today, one in every 150 Brazilians has an MRV that they call home. But we don’t stop there. Each development comes with the essential building blocks of a community such as daycare centers, health clinics, paved streets, green spaces, reforestation and much, much more. Because growth and urban development require the balance of social responsibility and sustainability, in addition to meeting the true needs of each community – an essential part of our DNA and an example of our commitment to the people of our communities. Click here to take a look at our company’s day-to-day routine and what we mean when we say: ‘to be MRV’.

Somos uma holding de investimentos, de controle familiar, que participa ativamente de diversos negócios nos setores imobiliário, alimentos e tecnologia, e que realiza uma gestão ativa de recursos próprios, buscando oportunidades de Investimentos em ativos líquidos e ilíquidos, no Brasil e no Exterior. Entre alguns dos principais negócios do Grupo, destacam-se: A Jereissati Participações, companhia aberta e negociada na B3 (“JPSA3”), que tem como principal ativo a participação de controle na Iguatemi Empresa de Shopping Centers S.A. A Iguatemi Empresa de Shopping Centers, também listada na B3 (“IGTA3”), foi a primeira companhia do setor de shopping centers no Brasil a ter suas ações negociadas na Bolsa. A Iguatemi possui mais de 20 propriedades entre Shopping Centers, Outlets e Prédios Comerciais. Os Empreendimentos da marca Iguatemi são sinônimos de diferenciação, qualidade e excelência nos mercados em que atuam. Além disso, a Iguatemi foi inovadora ao lançar em 2019 o Iguatemi 365, um marketplace focado em moda, presentes e lifestyle, com curadoria e administração Iguatemi e atuação em todo o território nacional. O Grande Moinho Cearense, um dos maiores players focados na atividade de moagem de trigo. Com plantas industriais em Fortaleza, Manaus e Teresina, o GMC produz uma farinha de trigo de alta qualidade, tanto para o mercado de panificação, massas e biscoitos, bem como para consumo doméstico através da marca Dona Maria. Em função da localização de suas plantas industriais, o GMC atende principalmente aos mercados das regiões Norte e Nordeste do Brasil. A Cadonau Investimentos é o Investment Office do Grupo Jereissati, e tem como objetivo originar, avaliar, negociar e monitorar investimentos em ativos líquidos e ilíquidos, no Brasil e no Exterior.

We are an international pharmaceutical company, governed by a non-profit foundation based in France (Suresnes). With a strong international presence in 148 countries and a turnover of 4,152 billion euros in 2017, we have a workforce of 21,600 employees worldwide. Totally independent, we reinvest 25% of our revenues (excluding generic drugs) in R&D and use all our profits for development. Corporate growth is driven by our constant pursuit of innovation in 5 areas of excellence: cardiovascular disease, immuno-inflammatory and neuropsychiatric diseases, cancer and diabetes, as well as our activities in high quality generic drugs. We currently have 35 candidate drug molecules, including 22 new molecular entities at various stages of clinical development. Our priorities are pathologies with high medical needs within our areas of expertise. To report an adverse reaction with one of our products, please visit our website servier.com.br